The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CytomX Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $10.26 Mil. CytomX Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1.33 Mil.
Hence, CytomX Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 7.72.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
CytomX Therapeutics Receivables Turnover Related Terms
CytomX Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for CytomX Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTMX vs ALLO, XOMA, OCS: Receivables Turnover Comparison
For the Biotechnology subindustry, CytomX Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytomX Therapeutics (CTMX) has a Receivables Turnover of 7.72 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CytomX Therapeutics and its competitors. According to the industry distribution chart, CytomX Therapeutics ranks #69 out of 843 companies in the Biotechnology industry, placing it in the top 8.2%.
Is CytomX Therapeutics' Receivables Turnover too high?
CytomX Therapeutics' current Receivables Turnover is 7.72. The Biotechnology industry median Receivables Turnover is 5.28. CytomX Therapeutics' value of 7.72 is 46.2% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #69 out of 843 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Receivables Turnover compare to ALLO and XOMA?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #69 out of 843 companies for Receivables Turnover. This places CytomX Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. CytomX Therapeutics' value of 7.72 is 46.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Receivables Turnover of 7.72 is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CytomX Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Receivables Turnover is 7.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.82 — trading 1264.3% above its estimated fair value. The current Receivables Turnover is 7.72 and 46.2% above the Biotechnology industry median of 5.28. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Receivables Turnover is 7.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.82 is trading 1264.3% above its estimated GF Value™ of $0.28.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
Receivables Turnover: 7.72
GF Value™: $0.28 vs. price of $3.82 (1264.3% above fair value)
Industry Position: 46.2% above the Biotechnology median (#69 of 843)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score
Get the complete analysis for CTMX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
